Oramed Pharmaceuticals Inc.
ORMP
$2.12
-$0.05-2.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.00M | 2.00M | -- | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.00M | 2.00M | -- | 0.00 | 0.00 |
| Cost of Revenue | 1.99M | 1.99M | -- | -- | -- |
| Gross Profit | 13.00K | 13.00K | -- | 0.00 | 0.00 |
| SG&A Expenses | 6.74M | 6.98M | 6.46M | 6.43M | 7.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.67M | 16.32M | 12.78M | 13.06M | 12.87M |
| Operating Income | -13.67M | -14.32M | -12.78M | -13.06M | -12.87M |
| Income Before Tax | -22.22M | -24.51M | -15.92M | 7.16M | 22.38M |
| Income Tax Expenses | 2.01M | 3.77M | 3.18M | 2.77M | 1.63M |
| Earnings from Continuing Operations | -24.22 | -28.28 | -19.10 | 4.39 | 20.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 61.00K | 41.00K | 43.00K | 73.00K | 112.00K |
| Net Income | -24.16M | -28.24M | -19.06M | 4.47M | 20.86M |
| EBIT | -13.67M | -14.32M | -12.78M | -13.06M | -12.87M |
| EBITDA | -13.53M | -14.15M | -12.59M | -12.85M | -12.65M |
| EPS Basic | -0.60 | -0.69 | -0.47 | 0.11 | 0.51 |
| Normalized Basic EPS | -0.39 | -0.40 | -0.38 | -0.39 | -0.16 |
| EPS Diluted | -0.62 | -0.71 | -0.49 | 0.10 | 0.50 |
| Normalized Diluted EPS | -0.39 | -0.40 | -0.38 | -0.39 | -0.16 |
| Average Basic Shares Outstanding | 164.54M | 163.75M | 163.36M | 163.21M | 162.76M |
| Average Diluted Shares Outstanding | 165.40M | 164.38M | 164.72M | 165.58M | 165.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |